IDEAYA Biosciences (IDYA) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving IDEAYA Biosciences (IDYA) right now is Darovasertib approval and launch in uveal melanoma: The positive OptimUM-02 readout (HR 0.42) supports an NDA filing in H2 2026 for first-line HLA-A*02:01-negative metastatic uveal melanoma, reviewed under the FDA's Real-Time Oncology Review pathway. Product revenue is ~$0 (pre-commercial; Q1 2026 collaboration revenue ~$6.6M). If that keeps playing out, the setup is favourable; the risk to it is as a clinical-stage biotech, IDEAYA has minimal product revenue and posts ongoing operating losses, so the equity is valued on pipeline expectations that can swing sharply on trial and regulatory news. No one can predict where IDYA trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive IDEAYA Biosciences (IDYA) higher?
1. Darovasertib approval and launch in uveal melanoma
The positive OptimUM-02 readout (HR 0.42) supports an NDA filing in H2 2026 for first-line HLA-A*02:01-negative metastatic uveal melanoma, reviewed under the FDA's Real-Time Oncology Review pathway. Uveal melanoma has few approved options, so approval could give IDEAYA a differentiated first commercial product. Neoadjuvant primary uveal melanoma (OptimUM trials, with eye-preservation data) represents a second, larger opportunity for the same molecule.
2. Synthetic-lethality and precision pipeline breadth
Beyond darovasertib, IDEAYA is advancing IDE397 (MAT2A) in MTAP-deleted cancers, including a planned combination with the PRMT5 inhibitor IDE892, plus IDE161 (PARG), IDE275 (Werner helicase), and IDE705 (Pol-theta helicase). This spread of biomarker-defined mechanisms means multiple independent shots on goal rather than reliance on a single asset.
3. IDE849 ADC and platform optionality
IDE849, a DLL3-targeting topoisomerase-I antibody-drug conjugate for solid tumors such as small cell lung cancer, is expected to enter a registrational trial by year-end 2026, adding a modality (ADCs) beyond small molecules. The DECIPHER CRISPR discovery platform continues to generate new synthetic-lethality targets, supporting a longer-term pipeline refresh.
4. Strong balance sheet and partnerships
About $973 million in cash and marketable securities (as of March 2026), with recent offering proceeds, funds operations into 2030 and reduces near-term financing pressure relative to many peers. The Servier collaboration on darovasertib and other partnerships provide external validation, cost sharing, and non-dilutive milestone potential.
What could weigh on IDYA?
As a clinical-stage biotech, IDEAYA has minimal product revenue and posts ongoing operating losses, so the equity is valued on pipeline expectations that can swing sharply on trial and regulatory news. The FDA could delay or decline the darovasertib NDA, or approval could come with a narrow label or slow commercial uptake in a rare indication. Earlier-stage programs (IDE397, IDE849, IDE161 and others) carry high failure rates typical of oncology drug development. Despite a large cash balance, continued spending and a recent shelf registration point to future dilution as a likely funding mechanism. The company also faces competition from established and emerging therapies in its target indications, and the stock is historically volatile around data catalysts.
Where IDYA trades today
A forecast starts from where the stock actually is. These are IDYA's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for IDYA as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a IDYA forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the IDYA guide and whether IDYA is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the IDYA outlook
The bottom line: what is driving IDEAYA Biosciences (IDYA) is Darovasertib approval and launch in uveal melanoma, with product revenue at ~$0 (pre-commercial; Q1 2026 collaboration revenue ~$6.6M). If that keeps playing out the setup is favourable; the risk is as a clinical-stage biotech, IDEAYA has minimal product revenue and posts ongoing operating losses, so the equity is valued on pipeline expectations that can swing sharply on trial and regulatory news. No one can predict the price, so treat any IDYA forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around IDYA with Walnut
Use IDEAYA Biosciences as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for IDEAYA Biosciences (IDYA)?
+
No one can reliably predict where IDYA will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push IDEAYA Biosciences higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive IDYA higher?
+
The main growth drivers are Darovasertib approval and launch in uveal melanoma; Synthetic-lethality and precision pipeline breadth; IDE849 ADC and platform optionality. Whether they play out is the real question, not a guaranteed path.
What are the risks to IDYA?
+
As a clinical-stage biotech, IDEAYA has minimal product revenue and posts ongoing operating losses, so the equity is valued on pipeline expectations that can swing sharply on trial and regulatory news. The FDA could delay or decline the darovasertib NDA, or approval could come with a narrow label or slow commercial uptake in a rare indication. Earlier-stage programs (IDE397, IDE849, IDE161 and others) carry high failure rates typical of oncology drug development. Despite a large cash balance, continued spending and a recent shelf registration point to future dilution as a likely funding mechanism. The company also faces competition from established and emerging therapies in its target indications, and the stock is historically volatile around data catalysts.
Will IDYA stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. IDEAYA Biosciences's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is IDYA a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the IDYA "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.